|
|
This article does not cite any references or sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (October 2006) |
|
Enoximone
|
|
| Systematic (IUPAC) name | |
| 4-methyl-5-{[4-(methylsulfanyl)phenyl]carbonyl}-2,3-dihydro-1H-imidazol-2-one | |
| Identifiers | |
| CAS number | 77671-31-9 |
| ATC code | C01CE03 |
| PubChem | 53708 |
| Chemical data | |
| Formula | C12H12N2O2S |
| Mol. mass | 248.302 g/mol |
| SMILES | eMolecules & PubChem |
| Pharmacokinetic data | |
| Bioavailability | 50% (oral) |
| Protein binding | 85% |
| Metabolism | Hepatic oxidation |
| Half life | 4 to 10 hours |
| Excretion | Renal (60 to 70%) |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Intravenous |
| |
|
Enoximone (INN, trade name Perfan) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure. Selective for phosphodiesterase 3
|
||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)




